China IBD market is estimated to grow significantly at a CAGR of around 5.8% during the forecast period. With the huge number of smokers in China, rapid industrialization, and changing lifestyle, the rate of IBD prevalence is estimated to increase in recent decade. These factors further raises the risk of IBD and contribute in the rising demand of diagnosis and treatment solutions thus creating significant market in the country. According to the World Bank, China had reported 49.2% of total males, smokes regularly in 2014, while the figure was 48.7% and 48.4% in 2015 and 2016 respectively. Smoking causes an adverse effect on small and large intestines, which as a result increasing the prevalence rate of IBD that further contribute to the growth of the market.

Request a Free Sample of our China Inflammatory Bowel Disease (IBD) Market: https://www.omrglobal.com/request-sample/china-ibd-inflammatory-bowel-disease-market

China IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. China IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

A full Report of China Inflammatory Bowel Disease (IBD) Market is Available at: https://www.omrglobal.com/industry-reports/china-ibd-inflammatory-bowel-disease-market

China Inflammatory Bowel Disease IBD Market Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease
• China IBD Market by Diagnostics
• Blood and Stool Tests
• Endoscopies,
• Ultrasound
• X-Ray
• China IBD Market by Therapeutics
• Surgery
• Anti- Inflammatory Drug Administration
• Steroids
• Immunosuppressant
• Biological Drugs
• Amino salicylates
• Others

Company Profiles

• AbbVie Inc.
• Allergan, PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Mercator Pharmaceutical Solutions
• Pfizer Inc.
• Sanofi S.A.
• Takeda pharmaceutical Co., Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-ibd-inflammatory-bowel-disease-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404